Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
Sienna Senior Living Inc. ("Sienna" or the "Company") today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of November 2024, representing $0.936 ...
Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...